ADDING PERTUZUMAB IN NEOADJUVANT TREATMENT OF PATIENTS WITH HER2(+) BREAST CANCER IN SPAIN: A COST OFFSETS STUDY - Albanell, J.; Ciruelos, E.; Colomer, R.; De la Haba, J.; Martin, M.; De Salas-Cansado, M.; Munoz-Molina, B.; Tournier, C.; Thuresson, P.; Schleich, W.;MORSE Hlth Technology Assessment; Global Pricing Market Access (Basic & Clinical Pharmacology & Toxicology, 2015)